JP2020529410A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529410A5
JP2020529410A5 JP2020505208A JP2020505208A JP2020529410A5 JP 2020529410 A5 JP2020529410 A5 JP 2020529410A5 JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020529410 A5 JP2020529410 A5 JP 2020529410A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044610 external-priority patent/WO2019028027A1/en
Publication of JP2020529410A publication Critical patent/JP2020529410A/ja
Publication of JP2020529410A5 publication Critical patent/JP2020529410A5/ja
Priority to JP2023075458A priority Critical patent/JP2023106433A/ja
Priority to JP2025092507A priority patent/JP2025131681A/ja
Pending legal-status Critical Current

Links

JP2020505208A 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質 Pending JP2020529410A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023075458A JP2023106433A (ja) 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質
JP2025092507A JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539421P 2017-07-31 2017-07-31
US62/539,421 2017-07-31
PCT/US2018/044610 WO2019028027A1 (en) 2017-07-31 2018-07-31 PROTEINS BINDING TO NKG2D, CD16 AND FLT3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023075458A Division JP2023106433A (ja) 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2020529410A JP2020529410A (ja) 2020-10-08
JP2020529410A5 true JP2020529410A5 (https=) 2021-09-24

Family

ID=65233032

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505208A Pending JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質
JP2023075458A Pending JP2023106433A (ja) 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023075458A Pending JP2023106433A (ja) 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Country Status (15)

Country Link
US (1) US20200165344A1 (https=)
EP (1) EP3661554A4 (https=)
JP (3) JP2020529410A (https=)
KR (2) KR20200033302A (https=)
CN (1) CN111132698A (https=)
AU (2) AU2018309712A1 (https=)
BR (1) BR112020001972A2 (https=)
CA (1) CA3070986A1 (https=)
CO (1) CO2020001981A2 (https=)
EA (1) EA202090387A1 (https=)
IL (1) IL272374A (https=)
MA (1) MA49769A (https=)
MX (1) MX2020001257A (https=)
SG (1) SG11202000632QA (https=)
WO (1) WO2019028027A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
JOP20200234A1 (ar) 2018-03-27 2020-09-15 Xyphos Biosciences Inc نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية.
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
SG11202104352XA (en) 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
PE20221316A1 (es) * 2019-10-15 2022-09-07 Dragonfly Therapeutics Inc Proteinas que se unen a nkg2d, cd16 y flt3
CN115768463A (zh) * 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16及びclec12aに結合するタンパク質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2023274183A1 (zh) * 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
WO2026052582A1 (en) 2024-09-04 2026-03-12 Red Ridge Bio Ag Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
JP6628966B2 (ja) * 2012-06-14 2020-01-15 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells

Similar Documents

Publication Publication Date Title
JP2020529410A5 (https=)
JP2023106433A5 (https=)
JP2021098732A5 (https=)
Krah et al. Engineering bispecific antibodies with defined chain pairing
JP2023052214A5 (https=)
JP2020507328A5 (https=)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2021534096A5 (https=)
JP2022551969A5 (https=)
JP2022516557A5 (https=)
JP2022545196A5 (https=)
JP2021533159A5 (https=)
JP2019023184A5 (https=)
JP2020510646A5 (https=)
JP2023526774A5 (https=)
JP2020508997A5 (https=)
JP2020521448A5 (https=)
JP2019536430A5 (https=)
JP2020507577A5 (https=)
JP2023538945A5 (https=)
JP2020531525A5 (https=)
JP2022537931A5 (https=)
CA3232364A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CN106397598B (zh) 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
JP2023532129A5 (https=)